SciSparc Provides Updates Upon Conclusion of 2021

/PRNewswire/ -- SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of...

Related Keywords

Yale University ,Connecticut ,United States ,Australia ,Japan ,Israel ,Helsinki ,Eteläuomen Läi ,Finland ,New Haven ,Australian ,America ,Israeli ,Japanese ,Itzhak Shrem ,Nicola Maggio ,Amitai Weiss ,Kirsten Mueller Vahl ,Tuan Trang ,Scisparc Ltd ,Sheba Fund For Health Services ,Department Of Comparative Biology Experimental Medicine ,Prnewswire Scisparc Ltd ,Nasdaq ,Chaim Sheba Medical Center ,Hanover Medical School ,Helsinki Committee ,Japanese Patent Office ,Australian Patent Office ,Child Study Center At Yale University ,Department Of Psychiatry ,Israeli Medical Center ,Exchange Commission ,University Of Calgary ,Company Or Scisparc ,Israeli Ministry Of Health ,Nasdaq Capital Market ,Tourette Syndrome ,Autism Spectrum Disorder ,North America ,Chief Executive Officer ,Nasdaq Capital ,Hanover Medical ,Child Study Center ,Israeli Ministry ,Clinical Trial ,Sheba Fund ,Health Services ,Status Epilepticus ,Israeli Medical Cannabis Unit ,Associate Professor ,Comparative Biology ,Experimental Medicine ,Looking Statements ,Private Securities Litigation Reform Act ,Annual Report ,